BUY Retatrutide 8mg
Retatrutide (LY3437943) is an investigational, once-weekly injectable peptide developed by Eli Lilly for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). The 8mg dose, administered via subcutaneous injection, is a mid-to-high maintenance dose in clinical trials, reached after titrating from 2mg and 4mg to optimize efficacy and tolerability. Not yet FDA-approved, it’s available only through phase 3 TRIUMPH trials (ongoing until 2026).
retatrutide for sale
Mechanisms of Action
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and slows gastric emptying, GIP enhances insulin sensitivity and fat metabolism, and glucagon boosts energy expenditure by promoting fat burning. With a ~6-day half-life, it delivers sustained effects. Phase 2 trials showed 8mg achieving ~22.8% weight loss and ~1.8% HbA1c reduction over 48 weeks, surpassing lower doses.
retatrutide peptide buy
Weight Loss: Achieves ~20–23% body weight loss (45–55 lbs) at 8mg with diet and exercise.
Blood Sugar Control: Lowers HbA1c by ~1.8% in type 2 diabetes patients.
Liver Health: Reduces liver fat by ~80% in MASLD patients, per phase 2 data.
Cardiometabolic Health: Lowers blood pressure, triglycerides, and LDL cholesterol.
Appetite suppression and metabolic improvements are evident within 4–8 weeks.
retatrutide price
Dosage and Administration
Start at 2mg weekly for 4 weeks, escalate to 4mg, then 8mg, with at least 4 weeks per step. Inject into the abdomen, thigh, or upper arm, rotating sites weekly. Administer any time of day, with or without food. Escalate to 12mg if prescribed. Store vials refrigerated (36–46°F). If a dose is missed, inject within 4 days or skip until the next week.
buy retatrutide
Safety and Side Effects
Common side effects include nausea, vomiting, diarrhea, and constipation (20–35%), peaking during escalation. Serious risks include transient heart rate increases and rare pancreatitis. Not suitable for those with thyroid cancer history or severe liver/renal impairment. Monitor for severe abdominal pain or allergic reactions. Long-term data is pending.
Legal Status
Not FDA-approved; available only in clinical trials or as a research peptide from select pharmacies. Banned by WADA.
Reviews
There are no reviews yet.